William Rowe

Clinical targeting of HIV capsid protein with a long-acting small molecule

John O. Link, Martin S. Rhee, Winston C. Tse et al. · Nature · 2020 · 421 citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +12

Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B

Stéphane Daffis, Scott Balsitis, Jason Chamberlain et al. · Hepatology · 2020 · 72 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent

Raju Subramanian, Jennifer Tang, Jim Zheng et al. · Molecular Pharmaceutics · 2023 · 48 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges

Samuel J. Vidal, Elena Bekerman, Derek Hansen et al. · Nature · 2021 · 27 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacokinetics +17

Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion

Elijah Weber, Raju Subramanian, William Rowe et al. · Clinical Pharmacokinetics · 2024 · 17 citations

Medicine, Pharmacokinetics, Pharmacology +15